[{"indications": "Indications\u00a0\n(From 6.1.2.3 Other antidiabetic drugs: British National Formulary)\n6.1.2.3 Other antidiabetic drugs", "name": "EXENATIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs", "EXENATIDE"], "cautions": "Cautions\u00a0elderly; pancreatitis (see below); may cause weight loss greater than 1.5\u00a0kg weekly; interactions: Appendix 1 (antidiabetics)Pancreatitis\u00a0Severe pancreatitis (sometimes fatal),\r\nincluding haemorrhagic or necrotising pancreatitis, has been reported\r\nrarely. Patients or their carers should be told how to\r\nrecognise signs and symptoms of pancreatitis and advised to seek prompt\r\nmedical attention if symptoms such as abdominal pain, nausea, and\r\nvomiting develop; discontinue permanently\r\nif pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances including nausea,\r\nvomiting, diarrhoea, dyspepsia, abdominal pain and distension, gastro-oesophageal\r\nreflux disease, decreased appetite, weight loss, headache, dizziness,\r\nagitation, asthenia, hypoglycaemia, increased sweating, injection-site\r\nreactions, antibody formation; less commonly pancreatitis\r\n(see Cautions above); rarely alopecia; very\r\nrarely anaphylactic reactions; also reported constipation,\r\nflatulence, eructation, dehydration, taste disturbance, renal impairment,\r\ndrowsiness, rash, pruritus, urticaria, and angioedema", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/218696.htm", "doses": ["By subcutaneous injection, adult over 18 years, initially 5\u00a0micrograms twice\r\ndaily within 1 hour before 2 main meals (at least 6 hours apart),\r\nincreased if necessary after at least 1 month to max. 10\u00a0micrograms\r\ntwice daily", "If a dose is missed, continue with\r\nthe next scheduled dose\u2014do not administer after a\r\nmeal. Some oral medications should be taken at least 1 hour before\r\nor 4 hours after exenatide injection\u2014consult product literature for\r\ndetails", "Dose of concomitant sulfonylurea may need\r\nto be reduced"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies.\r\nWomen of child-bearing age should use effective contraception during\r\ntreatment with modified-release exenatide and for 12 weeks after discontinuation"}, {"indications": "Indications\u00a0\n(From 6.1.2.3 Other antidiabetic drugs: British National Formulary)\n6.1.2.3 Other antidiabetic drugs", "name": "EXENATIDE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs", "EXENATIDE", "Modified release"], "cautions": "Cautions\u00a0elderly; pancreatitis (see below); may cause weight loss greater than 1.5\u00a0kg weekly; interactions: Appendix 1 (antidiabetics)Pancreatitis\u00a0Severe pancreatitis (sometimes fatal),\r\nincluding haemorrhagic or necrotising pancreatitis, has been reported\r\nrarely. Patients or their carers should be told how to\r\nrecognise signs and symptoms of pancreatitis and advised to seek prompt\r\nmedical attention if symptoms such as abdominal pain, nausea, and\r\nvomiting develop; discontinue permanently\r\nif pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances including nausea,\r\nvomiting, diarrhoea, dyspepsia, abdominal pain and distension, gastro-oesophageal\r\nreflux disease, decreased appetite, weight loss, headache, dizziness,\r\nagitation, asthenia, hypoglycaemia, increased sweating, injection-site\r\nreactions, antibody formation; less commonly pancreatitis\r\n(see Cautions above); rarely alopecia; very\r\nrarely anaphylactic reactions; also reported constipation,\r\nflatulence, eructation, dehydration, taste disturbance, renal impairment,\r\ndrowsiness, rash, pruritus, urticaria, and angioedema", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/218697.htm", "doses": ["By subcutaneous injection, adult over 18 years, initially 5\u00a0micrograms twice\r\ndaily within 1 hour before 2 main meals (at least 6 hours apart),\r\nincreased if necessary after at least 1 month to max. 10\u00a0micrograms\r\ntwice daily", "If a dose is missed, continue with\r\nthe next scheduled dose\u2014do not administer after a\r\nmeal. Some oral medications should be taken at least 1 hour before\r\nor 4 hours after exenatide injection\u2014consult product literature for\r\ndetails", "by subcutaneous injection, adult over 18 years, 2\u00a0mg once weekly", "Name[Bydureon\u00ae (Lilly)  ] Injection, m/r, powder for reconstitution,\r\nexenatide, net price 2-mg vial (with solvent) = \u00a318.34. \r\n    Label:\r\n    10, counselling, administrationDose\u00a0by subcutaneous injection, adult over 18 years, 2\u00a0mg once weeklyCounselling\u00a0Patients changing from standard-release\r\nexenatide formulation may experience initial transient increase in\r\nblood glucose. Some oral medications should be taken at least 1 hour\r\nbefore or 4 hours after exenatide injection\u2014consult product literature\r\nfor detailsNote\u00a0Dose of concomitant sulfonylurea may need\r\nto be reducedImportant\u00a0Effect of Bydureon\u00ae may persist for 10 weeks after discontinuation"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies.\r\nWomen of child-bearing age should use effective contraception during\r\ntreatment with modified-release exenatide and for 12 weeks after discontinuation"}]